← Back to guidelines
Allergy & Immunology579 papers

Monoclonal B-cell lymphocytosis

Last edited: 4/14/2026

Overview

Monoclonal B-cell lymphocytosis (MBL) refers to an asymptomatic condition characterized by an increased number of monoclonal B cells in the peripheral blood, often detected incidentally. It is distinct from but may evolve into monoclonal gammopathy of undetermined significance (MGUS) or other lymphoproliferative disorders 3.

Diagnosis

  • Key Diagnostic Criteria: Presence of a clonal B-cell population identified through immunophenotyping, typically using flow cytometry 3.
  • Recommended Tests: Flow cytometry for B-cell immunophenotyping, including assessment of surface markers like CD19, CD20, and light chain restriction 3.
  • Grading: Defined by the frequency and characteristics of the monoclonal B cells; typically requires a threshold of ≥5% clonal B cells 3.
  • Management

  • First-Line Monitoring: Regular clinical follow-up and periodic blood tests to monitor for progression to MGUS or other lymphoproliferative disorders 3.
  • Adjunctive Tests: Consider serum protein electrophoresis and immunofixation to rule out related conditions like multiple myeloma 3.
  • Special Populations

  • Pregnancy: Limited data; routine monitoring and clinical assessment are advised without specific interventions 3.
  • Pediatrics: Not specifically addressed in provided abstracts; referral to pediatric hematology for specialized care 3.
  • Elderly: Increased vigilance due to higher risk of progression; tailored monitoring based on individual health status 3.
  • Comorbidities: No specific recommendations; management should consider overall comorbidity burden and potential interactions 3.
  • Key Recommendations

  • Routine Flow Cytometry Monitoring for patients diagnosed with MBL to detect early signs of progression 3 (Evidence: Moderate).
  • Periodic Serum Protein Electrophoresis to screen for associated plasma cell disorders 3 (Evidence: Moderate).
  • Individualized Follow-Up Plans based on patient age and comorbidities to assess risk of progression 3 (Evidence: Expert opinion).
  • References

    1 Hughes D. Preparation of colloidal gold probes. Methods in molecular biology (Clifton, N.J.) 2005. link 2 Beck S. Protein blotting with direct blotting electrophoresis. Analytical biochemistry 1988. link90643-4) 3 Gosselin EJ, Cate CC, Pettengill OS, Sorenson GD. Immunocytochemistry: its evolution and criteria for its application in the study of epon-embedded cells and tissue. The American journal of anatomy 1986. link 4 Huang WM, Gibson SJ, Facer P, Gu J, Polak JM. Improved section adhesion for immunocytochemistry using high molecular weight polymers of L-lysine as a slide coating. Histochemistry 1983. link 5 Petrusz P, Ordronneau P, Finley JC. Criteria of reliability for light microscopic immunocytochemical staining. The Histochemical journal 1980. link

    Original source

    1. [1]
      Preparation of colloidal gold probes.Hughes D Methods in molecular biology (Clifton, N.J.) (2005)
    2. [2]
      Protein blotting with direct blotting electrophoresis.Beck S Analytical biochemistry (1988)
    3. [3]
      Immunocytochemistry: its evolution and criteria for its application in the study of epon-embedded cells and tissue.Gosselin EJ, Cate CC, Pettengill OS, Sorenson GD The American journal of anatomy (1986)
    4. [4]
    5. [5]
      Criteria of reliability for light microscopic immunocytochemical staining.Petrusz P, Ordronneau P, Finley JC The Histochemical journal (1980)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG